Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Xingya Li, MD"'
Autor:
Xiaorong Dong, MD, PhD, Xingya Li, MD, Jianhua Chen, MD, Shenglin Ma, MD, Deguang Mu, MD, Jie Hu, MD, PhD, Shun Lu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100449- (2023)
Introduction: c-MET is an important therapeutic target for various cancers; however, the People’s Republic of China currently retails only one specific c-MET inhibitor. Our preclinical study has revealed the high selectivity of HS-10241 to suppress
Externí odkaz:
https://doaj.org/article/7a976e919ca64687a5bc34303f3eb7b5
Autor:
Shun Lu, MD, Jian Fang, MD, Xingya Li, MD, Lejie Cao, MD, Jianying Zhou, MD, Qisen Guo, MD, Zongan Liang, MD, Ying Cheng, MD, Liyan Jiang, MD, Nong Yang, MD, Zhigang Han, MD, Jianhua Shi, MD, Yuan Chen, MD, Hua Xu, MD, Helong Zhang, MD, Gongyan Chen, MD, Rui Ma, MD, Sanyuan Sun, MD, Yun Fan, MD, Songhua Fan, MD, Jie Yu, MD, Puhan Lu, PhD, Xian Luo, MS, Weiguo Su, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 10, Pp 100407- (2022)
Introduction: Savolitinib has been found to have encouraging antitumor activity and a favorable safety profile in Chinese patients with pulmonary sarcomatoid carcinoma and other NSCLCs with MET exon 14 skipping alterations (MET ex14 positive) at the
Externí odkaz:
https://doaj.org/article/a7ca95375de14255b657fbafab37ec69
Publikováno v:
Technology in Cancer Research & Treatment, Vol 21 (2022)
Objective This retrospective study aimed to investigate the clinical features of lung cancer patients with leptomeningeal metastasis (LM) and explore the clinical efficacy and tolerance of intrathecal pemetrexed (IP) combined with systemic antitumor
Externí odkaz:
https://doaj.org/article/7954bd76f1404ce3977de3d2b6b543e9